Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGend Therapeutics CoROCO:6733 73 Cyclically Adjusted PS Ratio is 41.29 as of Aug. 05, 2026, which is 26% below its 10-year median of 55.76. GuruFocus rates ROCO:6733 with a GF Score™ of 73/100 and a GF Value™ of NT$59.57 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 538 Biotechnology companies, BioGend Therapeutics Co ranks worse than 89.03% on this metric.
The historical rank and industry rank for BioGend Therapeutics Co's Cyclically Adjusted PS Ratio or its related term are showing as below:
ROCO:6733'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 39.54 Med: 55.76 Max: 58.3
Current: 39.54
During the past 10 years, BioGend Therapeutics Co's highest Cyclically Adjusted PS Ratio was 58.30. The lowest was 39.54. And the median was 55.76.
ROCO:6733's Cyclically Adjusted PS Ratio is ranked worse than 89.03% of 538
companies
in the Biotechnology industry
Industry Median: 5.485
vs ROCO:6733: 39.54
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
BioGend Therapeutics Co's adjusted revenue per share data of for the fiscal year that ended in Dec25 was NT$1.801. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is NT$0.66 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
BioGend Therapeutics Co (ROCO:6733) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
BioGend Therapeutics Co Cyclically Adjusted PS Ratio Related Terms
BioGend Therapeutics Co Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for BioGend Therapeutics Co's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGend Therapeutics Co Cyclically Adjusted PS Ratio Chart
ROCO:6733 vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, BioGend Therapeutics Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGend Therapeutics Co Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioGend Therapeutics Co's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where BioGend Therapeutics Co's Cyclically Adjusted PS Ratio falls into.
BioGend Therapeutics Co Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 41.29 mean?
BioGend Therapeutics Co (ROCO:6733) has a Cyclically Adjusted PS Ratio of 41.29 as of Aug. 05, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioGend Therapeutics Co and its competitors. This is 26% below median its historical median of 55.76. Over the past decade, BioGend Therapeutics Co's Cyclically Adjusted PS Ratio has ranged from 39.54 to 58.30. According to the industry distribution chart, BioGend Therapeutics Co ranks #479 out of 538 companies in the Biotechnology industry, placing it in the top 89%.
Is BioGend Therapeutics Co's Cyclically Adjusted PS Ratio too high?
BioGend Therapeutics Co's current Cyclically Adjusted PS Ratio of 41.29 is 26% below median its 10-year median of 55.76. Over the past 10 years, this metric has ranged from a low of 39.54 to a high of 58.30. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.49. BioGend Therapeutics Co's value of 41.29 is 652.8% above this industry median. Based on the distribution chart, BioGend Therapeutics Co ranks #479 out of 538 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioGend Therapeutics Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGend Therapeutics Co's Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioGend Therapeutics Co ranks #479 out of 538 companies for Cyclically Adjusted PS Ratio. This places BioGend Therapeutics Co in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.49. BioGend Therapeutics Co's value of 41.29 is 652.8% above this benchmark. Historically, BioGend Therapeutics Co's own Cyclically Adjusted PS Ratio has ranged from 39.54 to 58.30 over the past decade. While the company's 10-year median is 55.76 vs. the industry median of 5.49, BioGend Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.49, based on 538 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGend Therapeutics Co's current Cyclically Adjusted PS Ratio of 41.29 is 652.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioGend Therapeutics Co and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGend Therapeutics Co's current Cyclically Adjusted PS Ratio is 41.29, which is 26% below median its own 10-year median of 55.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGend Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, BioGend Therapeutics Co (ROCO:6733) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$59.57, compared to a current price of NT$27.25 — trading 54.3% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 41.29, which is 26% below median its 10-year median of 55.76 and 652.8% above the Biotechnology industry median of 5.49. BioGend Therapeutics Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For BioGend Therapeutics Co (ROCO:6733), the current Cyclically Adjusted PS Ratio is 41.29 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGend Therapeutics Co (ROCO:6733) Overvalued in 2026?
Based on GuruFocus' analysis, BioGend Therapeutics Co stock appears to be undervalued.
The current stock price of NT$27.25 is trading 54.3% below its estimated GF Value™ of NT$59.57.
GuruFocus considers BioGend Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6733:
Cyclically Adjusted PS Ratio: 41.29 (26% below median its 10-year median of 55.76)
GF Value™: NT$59.57 vs. price of NT$27.25 (54.3% below fair value)
Industry Position: 652.8% above the Biotechnology median (#479 of 538)
No single metric tells the full story. See the ROCO:6733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGend Therapeutics Co Ltd is a Taiwan-based company involved in the research and development of orthopedic medical equipment and related products, and the sale of related products. It is involved in the research and development of inventive cartilage repair technology and products, adipose stem cell extraction technology, and others. Geographically, the company generates a majority of its revenue from Taiwan, followed by China, Malaysia, and other regions.
73GF Score
Get the complete analysis for ROCO:6733
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6733 has been successfully added to your 
